Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure.


Journal

Clinical interventions in aging
ISSN: 1178-1998
Titre abrégé: Clin Interv Aging
Pays: New Zealand
ID NLM: 101273480

Informations de publication

Date de publication:
2020
Historique:
received: 03 02 2020
accepted: 05 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 24 9 2020
Statut: epublish

Résumé

In Romania, robust data about the prevalence of obesity and heart failure are lacking, especially in the elderly; therefore, this study aims to analyze the profile of overweight and obese patients aged >65 years admitted to a Romanian hospital for worsening heart failure, and also their risk in the presence of comorbidities. This cross-sectional study was conducted in 126 consecutive elderly patients with overweight and obesity admitted to a Romanian hospital for worsening heart failure. They were divided into three groups: with reduced (<40%) - HFrEF, mid-range (40-49%) - HFmrEF and preserved (≥50%) ejection fraction - HFpEF. Obesity was defined according to the body mass index (BMI) status: obesity, ≥30 kg/m NT-proBNP values are negatively correlated with BMI only in patients with HFpEF. Creatinine clearance (p=0.0166), the presence of atrial fibrillation (p=0.0095) and NYHA functional class were independent predictors of increased NT-proBNP values. CCI score is negatively correlated with NT-proBNP values in patients with HFmrEF (r= -0.448, p=0.009) and HFpEF (r= -0.273, p=0.043). The CCI risk was not significantly different between the three groups. Elderly heart failure patients with overweight or obesity have particular characteristics in terms of NT-proBNP values and presence of comorbidities. In the studied population, NT-proBNP levels were strongly influenced by renal function, NYHA functional class, the presence of atrial fibrillation and left ventricular ejection fraction.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
In Romania, robust data about the prevalence of obesity and heart failure are lacking, especially in the elderly; therefore, this study aims to analyze the profile of overweight and obese patients aged >65 years admitted to a Romanian hospital for worsening heart failure, and also their risk in the presence of comorbidities.
PATIENTS AND METHODS METHODS
This cross-sectional study was conducted in 126 consecutive elderly patients with overweight and obesity admitted to a Romanian hospital for worsening heart failure. They were divided into three groups: with reduced (<40%) - HFrEF, mid-range (40-49%) - HFmrEF and preserved (≥50%) ejection fraction - HFpEF. Obesity was defined according to the body mass index (BMI) status: obesity, ≥30 kg/m
RESULTS RESULTS
NT-proBNP values are negatively correlated with BMI only in patients with HFpEF. Creatinine clearance (p=0.0166), the presence of atrial fibrillation (p=0.0095) and NYHA functional class were independent predictors of increased NT-proBNP values. CCI score is negatively correlated with NT-proBNP values in patients with HFmrEF (r= -0.448, p=0.009) and HFpEF (r= -0.273, p=0.043). The CCI risk was not significantly different between the three groups.
CONCLUSION CONCLUSIONS
Elderly heart failure patients with overweight or obesity have particular characteristics in terms of NT-proBNP values and presence of comorbidities. In the studied population, NT-proBNP levels were strongly influenced by renal function, NYHA functional class, the presence of atrial fibrillation and left ventricular ejection fraction.

Identifiants

pubmed: 32368021
doi: 10.2147/CIA.S248158
pii: 248158
pmc: PMC7184119
doi:

Substances chimiques

Peptide Fragments 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

547-556

Informations de copyright

© 2020 Dădârlat-Pop et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Circ J. 2017 Jun 23;81(7):966-973
pubmed: 28367843
Mayo Clin Proc. 2017 Feb;92(2):266-279
pubmed: 28109619
Eur Heart J. 2016 Oct 07;37(38):2869-2878
pubmed: 27071819
PLoS One. 2014 Aug 21;9(8):e105249
pubmed: 25144363
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Exp Ther Med. 2013 Jan;5(1):229-232
pubmed: 23251273
Scand J Public Health. 2018 Jul;46(5):522-529
pubmed: 29569525
Eur Heart J. 2017 Jun 21;38(24):1934-1936
pubmed: 28369264
Prog Cardiovasc Dis. 2016 Mar-Apr;58(5):537-47
pubmed: 26826295
Lancet. 2015 May 23;385(9982):2107-17
pubmed: 26009231
JACC Heart Fail. 2016 Sep;4(9):746-8
pubmed: 27522629
Eur J Heart Fail. 2017 Aug;19(8):971-973
pubmed: 28370920
Curr Cardiol Rep. 2017 Mar;19(3):19
pubmed: 28220465
Int J Obes (Lond). 2014 Aug;38(8):1110-4
pubmed: 24173404
PLoS One. 2015 Apr 07;10(4):e0123516
pubmed: 25848965
Am J Clin Pathol. 2010 Jan;133(1):14-23
pubmed: 20023254
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Clin Invest. 2014;44(3):303-8
pubmed: 24372567
Eur J Prev Cardiol. 2012 Oct;19(5):944-51
pubmed: 21856715
Eur J Heart Fail. 2015 May;17(5):527-33
pubmed: 25754836
Eur J Heart Fail. 2015 Jul;17(7):665-71
pubmed: 26079097
Diabetes Care. 2014 Nov;37(11):2899-908
pubmed: 25342830
Eur J Heart Fail. 2018 Feb;20(2):216-227
pubmed: 29148148
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):151-156
pubmed: 29852198
Eur Heart J. 2017 Jul 1;38(25):1951-1958
pubmed: 28873951
Aging Clin Exp Res. 2018 Aug;30(8):927-933
pubmed: 29124524
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
Obes Facts. 2015;8(6):402-24
pubmed: 26641646
Can J Cardiol. 2011 Mar-Apr;27(2):254-61
pubmed: 21459274
Int J Cardiol. 2014 Oct 20;176(3):611-7
pubmed: 25156856
Rev Esp Cardiol. 2011 Feb;64(2):140-9
pubmed: 21277668
J Card Fail. 2017 Aug;23(8):628-651
pubmed: 28461259
J Am Coll Cardiol. 2005 Sep 6;46(5):838-44
pubmed: 16139134

Auteurs

Alexandra Dădârlat-Pop (A)

Cardiology Department, "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Adela Sitar-Tăut (A)

Internal Medicine Department, 2nd Department, Medical Clinic IV, Cluj-Napoca, Romania.

Dumitru Zdrenghea (D)

Internal Medicine Department, Cardiology - Rehabilitation Department, Clinical Rehabilitation Hospital, Cluj-Napoca, Romania.

Bogdan Caloian (B)

Internal Medicine Department, Cardiology - Rehabilitation Department, Clinical Rehabilitation Hospital, Cluj-Napoca, Romania.

Raluca Tomoaia (R)

Cardiology Department, "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Dana Pop (D)

Internal Medicine Department, Cardiology - Rehabilitation Department, Clinical Rehabilitation Hospital, Cluj-Napoca, Romania.

Anca Buzoianu (A)

Department of Pharmacology, Toxicology and Clinical Pharmacology, "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH